{
  "meta": {
    "id": "test19",
    "title": "T-20 Pharmacology Test-4 (CVS) - 29-06-2023 - 2023-06-29",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Which of the following drugs acts as an antagonist of nicotinic receptors and is useful as an antidote for nicotine poisoning?",
      "options": [
        {
          "label": "A",
          "text": "Trimethoprim",
          "correct": false
        },
        {
          "label": "B",
          "text": "Triazolam",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trimethaphan",
          "correct": true
        },
        {
          "label": "D",
          "text": "Triclabendazole",
          "correct": false
        }
      ],
      "correct_answer": "C. Trimethaphan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Trimethaphan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Trimethoprim</li><li>\u2022 Option A: Trimethoprim</li><li>\u2022 Trimethoprim is an antibiotic that inhibits bacterial dihydrofolate reductase. It has no action on nicotinic receptors and is not used as an antidote for nicotine poisoning.</li><li>\u2022 Option B: Triazolam</li><li>\u2022 Option B: Triazolam</li><li>\u2022 Triazolam is a short-acting benzodiazepine used for the treatment of insomnia. It does not act on nicotinic receptors and is not relevant for treating nicotine poisoning.</li><li>\u2022 Option D: Triclabendazole</li><li>\u2022 Option D: Triclabendazole</li><li>\u2022 Triclabendazole is an antiparasitic drug used to treat infections caused by liver flukes. It does not affect nicotinic receptors and is not used as an antidote for nicotine poisoning.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Trimethaphan is a nicotinic receptor antagonist that can be used as an antidote for nicotine poisoning by blocking the effects of nicotine at autonomic ganglia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3074538f",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT true about the use of beta blockers in CHF?",
      "options": [
        {
          "label": "A",
          "text": "These should be started at very low dose and slowly titrated upwards",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carvedilol is most widely used beta blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "These are drug of choice in acute decompensated heart failure",
          "correct": true
        },
        {
          "label": "D",
          "text": "These can reduce mortality in CHF patients",
          "correct": false
        }
      ],
      "correct_answer": "C. These are drug of choice in acute decompensated heart failure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. These are drug of choice in acute decompensated heart failure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: These should be started at very low dose and slowly titrated upwards</li><li>\u2022 Option A: These should be started at very low dose and slowly titrated upwards</li><li>\u2022 Beta blockers should indeed be started at very low doses and slowly titrated upwards. This cautious approach is necessary to avoid acute decompensation and to allow the patient\u2019s body to adjust to the medication gradually.</li><li>\u2022 Option B: Carvedilol is most widely used beta blocker</li><li>\u2022 Option B: Carvedilol is most widely used beta blocker</li><li>\u2022 Carvedilol is one of the most widely used beta blockers in the management of chronic heart failure due to its non-selective beta-blocking properties and additional alpha-blocking effects, which can provide beneficial vasodilation.</li><li>\u2022 Option D: These can reduce mortality in CHF patients</li><li>\u2022 Option D: These can reduce mortality in CHF patients</li><li>\u2022 Beta blockers have been shown to reduce mortality in patients with chronic heart failure. They help by reducing the heart rate, decreasing myocardial oxygen demand, and preventing the detrimental effects of chronic sympathetic nervous system activation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Beta blockers are crucial in managing chronic heart failure, started at low doses and titrated slowly to avoid acute decompensation. They are not used in acute decompensated heart failure but can reduce mortality in chronic heart failure patients.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2ab112cb",
      "audio": ""
    },
    {
      "text": "Pure action potential prolonging drug without any other effect on action potential is :",
      "options": [
        {
          "label": "A",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ibutilide",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lignocaine",
          "correct": false
        }
      ],
      "correct_answer": "C. Ibutilide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Ibutilide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Quinidine</li><li>\u2022 Option A: Quinidine</li><li>\u2022 Quinidine is a class IA antiarrhythmic drug that not only prolongs the action potential but also has effects on sodium channels, leading to a decrease in the slope of phase 0 (depolarization) of the action potential.</li><li>\u2022 Option B: Amiodarone</li><li>\u2022 Option B: Amiodarone</li><li>\u2022 Amiodarone is a class III antiarrhythmic drug that prolongs the action potential duration but also has multiple effects on sodium, potassium, and calcium channels, as well as adrenergic receptors, making its action more complex and not purely limited to action potential prolongation.</li><li>\u2022 Option D: Lignocaine</li><li>\u2022 Option D: Lignocaine</li><li>\u2022 Lignocaine (also known as Lidocaine) is a class IB antiarrhythmic drug that primarily shortens the action potential duration and has effects on sodium channels, leading to a decrease in the slope of phase 0 (depolarization) of the action potential.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ibutilide is a pure action potential prolonging drug, primarily affecting potassium channels without other significant effects on the action potential, unlike other antiarrhythmics like amiodarone, lignocaine and quinidine, which have multiple channel effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c8e9123d",
      "audio": ""
    },
    {
      "text": "Which of the following is not a first line anti-hypertensive drug?",
      "options": [
        {
          "label": "A",
          "text": "Enalapril",
          "correct": false
        },
        {
          "label": "B",
          "text": "Telmisartan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metoprolol",
          "correct": true
        },
        {
          "label": "D",
          "text": "Amlodipine",
          "correct": false
        }
      ],
      "correct_answer": "C. Metoprolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Metoprolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Enalapril</li><li>\u2022 Option A: Enalapril</li><li>\u2022 Enalapril is an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors are commonly used as first-line agents in the management of hypertension due to their efficacy and benefits in reducing cardiovascular events.</li><li>\u2022 Option B: Telmisartan</li><li>\u2022 Option B: Telmisartan</li><li>\u2022 Telmisartan is an angiotensin II receptor blocker (ARB). ARBs are also considered first-line antihypertensive agents, particularly useful in patients who cannot tolerate ACE inhibitors.</li><li>\u2022 Option D: Amlodipine</li><li>\u2022 Option D: Amlodipine</li><li>\u2022 Amlodipine is a calcium channel blocker (CCB). Calcium channel blockers are first-line antihypertensive agents due to their effectiveness in lowering blood pressure and their favourable safety profile.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Beta-blockers like metoprolol are not considered first-line therapy for hypertension unless there are specific indications such as heart failure or post-myocardial infarction. Diuretics, ACE inhibitors, ARBs, and calcium channel blockers are preferred first-line antihypertensive drugs.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "85dd5b8c",
      "audio": ""
    },
    {
      "text": "A 44-year-old obese man has extremely high plasma triglyceride levels, but cholesterol levels are within normal limits. Following treatment with a drug specifically indicated for hypertriglyceridemia, triglyceride levels decrease to almost normal. Which of the following agents is most likely to have caused this desired change?",
      "options": [
        {
          "label": "A",
          "text": "Atorvastatin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cholestyramine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ezitemibe",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fenofibrate",
          "correct": true
        }
      ],
      "correct_answer": "D. Fenofibrate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Fenofibrate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Atorvastatin</li><li>\u2022 Option A: Atorvastatin</li><li>\u2022 Atorvastatin is an HMG-CoA reductase inhibitor (statin) primarily used to lower LDL cholesterol. While statins can modestly lower triglyceride levels, they are not the first choice for patients with isolated hypertriglyceridemia.</li><li>\u2022 Option B: Cholestyramine</li><li>\u2022 Option B: Cholestyramine</li><li>\u2022 Cholestyramine is a bile acid sequestrant that primarily lowers LDL cholesterol. It is not effective for significantly lowering triglyceride levels and is not indicated for isolated hypertriglyceridemia.</li><li>\u2022 Option C: Ezetimibe</li><li>\u2022 Option C: Ezetimibe</li><li>\u2022 Ezetimibe is a cholesterol absorption inhibitor that primarily lowers LDL cholesterol by inhibiting the absorption of cholesterol in the small intestine. It does not have a significant effect on triglyceride levels.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fenofibrate is the drug of choice for the treatment of hypertriglyceridemia, effectively reducing plasma triglyceride levels by activating PPAR-\u03b1 and increasing fatty acid oxidation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "19912a36",
      "audio": ""
    },
    {
      "text": "A patient with angina is started on a nitroglycerin transdermal delivery system (\u201cskin patch\u201d) for prophylaxis of his angina. He wears the patch 24 h a day, 7 days a week, except for the few minutes when he showers each day. Which of the following is the main concern with \u201caround-the-clock\u201d administration of this drug?",
      "options": [
        {
          "label": "A",
          "text": "Cyanide poisoning",
          "correct": false
        },
        {
          "label": "B",
          "text": "Development of tolerance to their vasodilator actions",
          "correct": true
        },
        {
          "label": "C",
          "text": "Onset of delayed, characteristic adverse responses including thrombosis and thrombocytopenia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paradoxical vasoconstriction leading to hypertension",
          "correct": false
        }
      ],
      "correct_answer": "B. Development of tolerance to their vasodilator actions",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Development of tolerance to their vasodilator actions</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Cyanide poisoning</li><li>\u2022 Option A: Cyanide poisoning</li><li>\u2022 Cyanide poisoning is associated with the use of sodium nitroprusside, not nitroglycerine. Nitroglycerine does not release cyanide as a byproduct.</li><li>\u2022 Option C: Onset of delayed, characteristic adverse responses including thrombosis and thrombocytopenia</li><li>\u2022 Option C: Onset of delayed, characteristic adverse responses including thrombosis and thrombocytopenia</li><li>\u2022 There is no significant association between nitroglycerine use and delayed adverse responses such as thrombosis or thrombocytopenia. These effects are not typical of nitroglycerine therapy.</li><li>\u2022 Option D: Paradoxical vasoconstriction leading to hypertension</li><li>\u2022 Option D: Paradoxical vasoconstriction leading to hypertension</li><li>\u2022 Nitroglycerine does not cause paradoxical vasoconstriction or hypertension. Its primary action is vasodilation, and tolerance development does not lead to paradoxical vasoconstriction.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Continuous, around-the-clock administration of nitroglycerine can lead to the development of tolerance, reducing the drug's effectiveness in preventing angina attacks. It is important to have a nitrate-free interval to prevent tolerance.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4035c272",
      "audio": ""
    },
    {
      "text": "Which of the following statements is WRONG about amiodarone?",
      "options": [
        {
          "label": "A",
          "text": "It is longest acting anti-arrhythmic drug",
          "correct": false
        },
        {
          "label": "B",
          "text": "It has positive inotropic action",
          "correct": true
        },
        {
          "label": "C",
          "text": "It contains iodine",
          "correct": false
        },
        {
          "label": "D",
          "text": "It causes pulmonary fibrosis",
          "correct": false
        }
      ],
      "correct_answer": "B. It has positive inotropic action",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. It has positive inotropic action</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: It is the longest acting anti-arrhythmic drug</li><li>\u2022 Option A: It is the longest acting anti-arrhythmic drug</li><li>\u2022 Amiodarone has a very long half-life, often measured in weeks to months, making it one of the longest-acting antiarrhythmic drugs.</li><li>\u2022 Option C: It contains iodine</li><li>\u2022 Option C: It contains iodine</li><li>\u2022 Amiodarone contains iodine in its molecular structure, which is partly responsible for its effects on thyroid function, potentially leading to either hypothyroidism or hyperthyroidism.</li><li>\u2022 Option D: It causes pulmonary fibrosis</li><li>\u2022 Option D: It causes pulmonary fibrosis</li><li>\u2022 One of the serious adverse effects of long-term amiodarone therapy is pulmonary fibrosis. This potentially life-threatening condition requires regular monitoring of pulmonary function in patients taking the drug.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Amiodarone is a long-acting antiarrhythmic drug that contains iodine and can cause serious side effects like pulmonary fibrosis. It does not have a positive inotropic effect on the heart.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6db529a2",
      "audio": ""
    },
    {
      "text": "This drug is approved for treatment of angina pectoris as well as for CHF. Its primary action is to decrease heart rate without affecting the AV nodal conduction or ventricular contractility. It may produce adverse effects on the vision. Which drug is being discussed about?",
      "options": [
        {
          "label": "A",
          "text": "Ivabradine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Levosimendan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Omapatrilat",
          "correct": false
        },
        {
          "label": "D",
          "text": "ARNI",
          "correct": false
        }
      ],
      "correct_answer": "A. Ivabradine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Ivabradine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option B: Levosimendan</li><li>\u2022 Option B: Levosimendan</li><li>\u2022 Levosimendan enhances cardiac contractility by sensitizing troponin C to calcium and opening ATP-sensitive potassium channels. It is primarily used for acute decompensated heart failure. Although it can cause hypotension and arrhythmias, it does not lead to significant visual disturbances, distinguishing it from ivabradine.</li><li>\u2022 Option C: Omapatrilat</li><li>\u2022 Option C: Omapatrilat</li><li>\u2022 Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). It was investigated for heart failure and hypertension but is not widely approved due to safety concerns, particularly the risk of angioedema. Unlike ivabradine, omapatrilat does not cause visual disturbances.</li><li>\u2022 Option D: ARNI (Angiotensin Receptor-Neprilysin Inhibitor)</li><li>\u2022 Option D: ARNI (Angiotensin Receptor-Neprilysin Inhibitor)</li><li>\u2022 ARNI, such as sacubitril/valsartan, combines neprilysin inhibition with angiotensin II receptor blockade, promoting vasodilation, natriuresis, and inhibition of the renin-angiotensin-aldosterone system. It is approved for heart failure with reduced ejection fraction (HFrEF). Common adverse effects of ARNI include hypotension, hyperkalemia, and renal impairment, but visual disturbances are not a typical side effect.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ivabradine is used to treat angina and heart failure by decreasing heart rate through selective inhibition of the If current in the sinoatrial node, without affecting AV nodal conduction or ventricular contractility. It can cause visual disturbances as a notable side effect.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd9cc487",
      "audio": ""
    },
    {
      "text": "A 67-year-old patient with Parkinsonism, hypertension and past history of MI is taking several drugs including low dose aspirin, ramipril, nitroglycerine, atorvastatin and pramipexole, He complains of muscle aches, pain, and tenderness. These affect the legs and trunk. There is no fever, bruising, or any recent history of muscle trauma. There is myoglobinuria, a clinically significant fall of creatinine clearance, and a rise of serum creatine kinase (CK) to levels nearly 10 times the upper limit of normal. Which of the following drugs is the most likely cause of these findings?",
      "options": [
        {
          "label": "A",
          "text": "Pramipexole to control his symptoms of Parkinsonism",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ramipril for hypertension",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nitroglycerin, sublingual, for effort-induced angina",
          "correct": false
        },
        {
          "label": "D",
          "text": "Atorvastatin to control his hypercholesterolemia and the associated risks",
          "correct": true
        }
      ],
      "correct_answer": "D. Atorvastatin to control his hypercholesterolemia and the associated risks",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Atorvastatin to control his hypercholesterolemia and the associated risks</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Pramipexole to control his symptoms of Parkinsonism</li><li>\u2022 Option A: Pramipexole to control his symptoms of Parkinsonism</li><li>\u2022 Pramipexole, a dopamine agonist used to treat Parkinson's disease, is not commonly associated with severe muscle-related side effects or rhabdomyolysis. Its side effects are more commonly related to the central nervous system, such as hallucinations and sleep disturbances.</li><li>\u2022 Option B: Ramipril for hypertension</li><li>\u2022 Option B: Ramipril for hypertension</li><li>\u2022 Ramipril, an ACE inhibitor used to treat hypertension, does not typically cause muscle aches, myopathy, or rhabdomyolysis. Its common side effects include cough, hyperkalemia, and renal impairment.</li><li>\u2022 Option C: Nitroglycerine, sublingual, for effort-induced angina</li><li>\u2022 Option C: Nitroglycerine, sublingual, for effort-induced angina</li><li>\u2022 Nitroglycerine, a nitrate used for angina, is not associated with muscle-related side effects. It primarily causes vasodilation, which can lead to side effects like headaches, dizziness, and hypotension.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Statins, such as atorvastatin, are known to cause muscle-related side effects, including myopathy and rhabdomyolysis. Patients on statin therapy presenting with muscle pain, elevated CK levels, and myoglobinuria should be evaluated for statin-induced rhabdomyolysis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d127c741",
      "audio": ""
    },
    {
      "text": "All of the following are indications of nitrates except:",
      "options": [
        {
          "label": "A",
          "text": "Diffuse esophageal spasm",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acute attack of angina",
          "correct": false
        },
        {
          "label": "C",
          "text": "Supraventricular arrhythmia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Biliary colic",
          "correct": false
        }
      ],
      "correct_answer": "C. Supraventricular arrhythmia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Supraventicular arrhythmia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Diffuse esophageal spasm Nitrates are indicated for diffuse esophageal spasm because they help relax smooth muscle, alleviating the spasm and associated chest pain.</li><li>\u2022 Option A: Diffuse esophageal spasm</li><li>\u2022 Option B: Acute attack of angina</li><li>\u2022 Option B: Acute attack of angina</li><li>\u2022 Nitrates are commonly used for the acute relief of angina pectoris. They act by dilating coronary arteries and reducing myocardial oxygen demand, providing rapid symptom relief.</li><li>\u2022 Option D: Biliary colic</li><li>\u2022 Option D: Biliary colic</li><li>\u2022 Nitrates can be used for biliary colic as they relax the smooth muscle in the biliary tract, helping to alleviate the pain caused by biliary spasm.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nitrates are indicated for conditions involving smooth muscle spasm and angina due to their vasodilatory properties. They are not used to treat supraventricular arrhythmias, as their effects do not influence the electrical activity of the heart in a way that would manage these types of arrhythmias.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "618c2e2a",
      "audio": ""
    },
    {
      "text": "A new antiarrhythmic drug is found to be effective against both atrial and ventricular arrhythmias. Its effect on action potential is shown as below. The effect of this new drug is most similar to:",
      "options": [
        {
          "label": "A",
          "text": "Lignocaine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Propanolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Encainide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Procainamide",
          "correct": true
        }
      ],
      "correct_answer": "D. Procainamide",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/29/picture1.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Procainamide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Lignocaine</li><li>\u2022 Option A: Lignocaine</li><li>\u2022 Lignocaine is a class IB antiarrhythmic drug that primarily shortens the action potential duration and acts on ischemic or depolarized tissues. It does not prolong the action potential as depicted in the graph.</li><li>\u2022 Option B: Propranolol</li><li>\u2022 Option B: Propranolol</li><li>\u2022 Propranolol is a class II antiarrhythmic (beta-blocker) that works by reducing sympathetic nervous system effects on the heart, decreasing heart rate and contractility. It does not have a significant effect on the action potential duration itself.</li><li>\u2022 Option C: Encainide</li><li>\u2022 Option C: Encainide</li><li>\u2022 Encainide is a class IC antiarrhythmic that works by significantly slowing conduction through the heart without a significant effect on the action potential duration. It does not exhibit the action potential prolonging effects seen in the graph.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Class IA antiarrhythmic drugs like procainamide and quinidine, decrease the slope of phase 0 and prolong the action potential duration by blocking sodium and potassium channels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e85ec145",
      "audio": ""
    },
    {
      "text": "The following statement is NOT true about sotalol?",
      "options": [
        {
          "label": "A",
          "text": "It is a non-selective beta-blocker",
          "correct": false
        },
        {
          "label": "B",
          "text": "It prolongs action potential duration of the heart",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is primarily excreted through bile following hepatic metabolism",
          "correct": true
        },
        {
          "label": "D",
          "text": "It can cause Torsades\u2019de Pointes",
          "correct": false
        }
      ],
      "correct_answer": "C. It is primarily excreted through bile following hepatic metabolism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. It is primarily excreted through bile following hepatic metabolism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: It is a non-selective beta-blocker</li><li>\u2022 Option A: It is a non-selective beta-blocker</li><li>\u2022 Sotalol is indeed a non-selective beta-blocker, meaning it blocks both beta-1 and beta-2 adrenergic receptors.</li><li>\u2022 Option B: It prolongs action potential duration of the heart</li><li>\u2022 Option B: It prolongs action potential duration of the heart</li><li>\u2022 Sotalol has class III antiarrhythmic properties, which means it prolongs the action potential duration and refractory period of cardiac cells by blocking potassium channels.</li><li>\u2022 Option D: It can cause Torsades de Pointes</li><li>\u2022 Option D: It can cause Torsades de Pointes</li><li>\u2022 One of the known adverse effects of sotalol is Torsades de Pointes, a specific type of polymorphic ventricular tachycardia associated with prolongation of the QT interval on the ECG.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sotalol is a non-selective beta-blocker with class III antiarrhythmic properties that prolong the action potential duration of the heart. It is primarily excreted unchanged by the kidneys and can cause Torsades de Pointes due to its effect on the QT interval.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6ca423c9",
      "audio": ""
    },
    {
      "text": "A drug effect that is produced by therapeutic doses of both timolol and amiodarone is blockade of:",
      "options": [
        {
          "label": "A",
          "text": "Cardiac Na + channels",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cardiac K + channels",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta-1 adrenoceptors",
          "correct": true
        },
        {
          "label": "D",
          "text": "Alpha-adrenoceptors",
          "correct": false
        }
      ],
      "correct_answer": "C. Beta-1 adrenoceptors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Beta-1 adrenoceptors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Cardiac Na+ channels</li><li>\u2022 Option A: Cardiac Na+ channels</li><li>\u2022 Amiodarone has some sodium channel blocking properties (class I antiarrhythmic effect), but timolol does not block cardiac sodium channels.</li><li>\u2022 Option B: Cardiac K+ channels</li><li>\u2022 Option B: Cardiac K+ channels</li><li>\u2022 Amiodarone blocks cardiac potassium channels, leading to prolonged action potentials (class III antiarrhythmic effect), but timolol does not block potassium channels.</li><li>\u2022 Option D: Alpha-adrenoceptors</li><li>\u2022 Option D: Alpha-adrenoceptors</li><li>\u2022 Neither timolol nor amiodarone is known for blocking alpha-adrenoceptors as a primary therapeutic effect. Amiodarone has some weak alpha-blocking properties, but this is not a significant part of its clinical use.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Both timolol, a non-selective beta-blocker, and amiodarone, a multi-class antiarrhythmic agent with beta-blocking properties, can block beta-1 adrenoceptors as part of their therapeutic actions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "661ae322",
      "audio": ""
    },
    {
      "text": "All of the following statements about sampatrilat are true except ?",
      "options": [
        {
          "label": "A",
          "text": "It inhibits both ACE as well as neprilysin",
          "correct": false
        },
        {
          "label": "B",
          "text": "It can cause angioedema",
          "correct": false
        },
        {
          "label": "C",
          "text": "It can cause hypokalemia",
          "correct": true
        },
        {
          "label": "D",
          "text": "It is used for treatment of CHF",
          "correct": false
        }
      ],
      "correct_answer": "C. It can cause hypokalemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. It can cause hypokalemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: It inhibits both ACE as well as neprilysin</li><li>\u2022 Option A: It inhibits both ACE as well as neprilysin</li><li>\u2022 Sampatrilat is known to inhibit both ACE and neprilysin, which helps in managing heart failure by reducing the breakdown of natriuretic peptides and angiotensin II.</li><li>\u2022 Option B: It can cause angioedema</li><li>\u2022 Option B: It can cause angioedema</li><li>\u2022 Similar to other ACE inhibitors, sampatrilat can cause angioedema, a potentially serious side effect related to increased bradykinin levels.</li><li>\u2022 Option D: It is used for treatment of CHF</li><li>\u2022 Option D: It is used for treatment of CHF</li><li>\u2022 Sampatrilat is used in the treatment of chronic heart failure (CHF) due to its dual inhibitory action on ACE and neprilysin, which helps to improve cardiac function and reduce symptoms.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sampatrilat is a dual inhibitor of ACE and neprilysin, used for the treatment of CHF. It can cause angioedema and hyperkalemia similar to other ACE inhibitors, but it does not cause hypokalemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ef5fa16a",
      "audio": ""
    },
    {
      "text": "You decide not to prescribe sildenafil in a patient because the patient told you that he is taking an antianginal drug. Which of the following can it be?",
      "options": [
        {
          "label": "A",
          "text": "Calcium channel blockers",
          "correct": false
        },
        {
          "label": "B",
          "text": "Beta adrenergic blockers",
          "correct": false
        },
        {
          "label": "C",
          "text": "Organic nitrates",
          "correct": true
        },
        {
          "label": "D",
          "text": "Angiotensin converting enzyme inhibitors",
          "correct": false
        }
      ],
      "correct_answer": "C. Organic nitrates",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Organic nitrates</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Calcium channel blockers</li><li>\u2022 Option A: Calcium channel blockers</li><li>\u2022 Calcium channel blockers are used as antianginal drugs, but they do not interact with sildenafil in a way that causes severe hypotension. Therefore, the use of calcium channel blockers does not contraindicate the prescription of sildenafil.</li><li>\u2022 Option B: Beta adrenergic blockers</li><li>\u2022 Option B: Beta adrenergic blockers</li><li>\u2022 Beta adrenergic blockers are also used in the treatment of angina. They primarily work by reducing heart rate and myocardial oxygen demand. They do not have the same severe interaction with sildenafil as organic nitrates do.</li><li>\u2022 Option D: Angiotensin converting enzyme inhibitors</li><li>\u2022 Option D: Angiotensin converting enzyme inhibitors</li><li>\u2022 ACE inhibitors are commonly used in treating hypertension and heart failure. They do not pose a significant risk of severe hypotension when used with sildenafil, unlike organic nitrates.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sildenafil should not be prescribed with organic nitrates due to the risk of severe hypotension. The combination of these drugs can cause a significant and potentially dangerous drop in blood pressure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2ea91cb2",
      "audio": ""
    },
    {
      "text": "Surinder singh developed acute CHF and was put on digitalis therapy. ECG of this patient revealed the presence of ventricular extrasystoles. Which of the following drugs can be administered safely to this patient in order to counteract this arrhythmia?",
      "options": [
        {
          "label": "A",
          "text": "Lignocaine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Lignocaine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Lignocaine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option B: Quinidine</li><li>\u2022 Option B: Quinidine</li><li>\u2022 Quinidine is a class 1A antiarrhythmic drug. It is not preferred in digitalis-induced arrhythmias because it can enhance the effects of digitalis and potentially worsen the arrhythmia.</li><li>\u2022 Option C: Amiodarone</li><li>\u2022 Option C: Amiodarone</li><li>\u2022 Amiodarone is a class III antiarrhythmic drug that can be used in various types of arrhythmias, including ventricular arrhythmias. However, in the context of acute digitalis toxicity, lignocaine is typically preferred due to its specific safety profile and effectiveness.</li><li>\u2022 Option D: All of the above</li><li>\u2022 Option D: All of the above</li><li>\u2022 This is incorrect because not all the listed drugs are safe or appropriate for managing digitalis-induced ventricular arrhythmias. Lignocaine is the preferred choice due to its safety and efficacy in this specific scenario.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lignocaine is the preferred treatment for digitalis-induced ventricular arrhythmias due to its rapid action and effectiveness, without exacerbating heart failure. Other antiarrhythmic drugs like quinidine and amiodarone are not as safe in this context.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "31ec1662",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT an adverse effect of chronic amiodarone therapy?",
      "options": [
        {
          "label": "A",
          "text": "Pulmonary Fibrosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypothyroidism",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperthyroidism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Systemic lupus erythematosis",
          "correct": true
        }
      ],
      "correct_answer": "D. Systemic lupus erythematosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Systemic lupus erythematosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Pulmonary Fibrosis</li><li>\u2022 Option A: Pulmonary Fibrosis</li><li>\u2022 Pulmonary fibrosis is a serious and well-documented adverse effect of chronic amiodarone therapy. It can be life-threatening and requires regular monitoring of lung function during treatment.</li><li>\u2022 Option B: Hypothyroidism</li><li>\u2022 Option B: Hypothyroidism</li><li>\u2022 Hypothyroidism is a common adverse effect of amiodarone because the drug contains iodine and can affect thyroid function. Regular thyroid function tests are recommended for patients on long-term amiodarone therapy.</li><li>\u2022 Option C: Hyperthyroidism</li><li>\u2022 Option C: Hyperthyroidism</li><li>\u2022 Hyperthyroidism can also occur as an adverse effect of amiodarone due to its high iodine content and its effects on thyroid hormone metabolism. This condition requires careful monitoring and management.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Chronic amiodarone therapy is associated with adverse effects such as pulmonary fibrosis, hypothyroidism, and hyperthyroidism, but not typically with SLE. Regular monitoring of lung and thyroid function is crucial in patients receiving long-term amiodarone.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "006ecbd0",
      "audio": ""
    },
    {
      "text": "Which of the following is true about laropiprant?",
      "options": [
        {
          "label": "A",
          "text": "A bile acid sequestrant",
          "correct": false
        },
        {
          "label": "B",
          "text": "A cholesterol absorption inhibitor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Has no hypolipidemic action, but combined with niacin",
          "correct": true
        },
        {
          "label": "D",
          "text": "MTP inhibitor used to decrease VLDL",
          "correct": false
        }
      ],
      "correct_answer": "C. Has no hypolipidemic action, but combined with niacin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Has no hypolipidemic action, but combined with niacin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: A bile acid sequestrant</li><li>\u2022 Option A: A bile acid sequestrant</li><li>\u2022 Bile acid sequestrants are a class of drugs that bind bile acids in the intestine, preventing their reabsorption and thereby lowering cholesterol levels. Examples include cholestyramine, colestipol, and colesevelam. Laropiprant is not a bile acid sequestrant.</li><li>\u2022 Option B: A cholesterol absorption inhibitor</li><li>\u2022 Option B: A cholesterol absorption inhibitor</li><li>\u2022 Cholesterol absorption inhibitors, such as ezetimibe, work by preventing the absorption of cholesterol from the intestine, leading to lower blood cholesterol levels. Laropiprant is not a cholesterol absorption inhibitor.</li><li>\u2022 Option D: MTP inhibitor used to decrease VLDL</li><li>\u2022 Option D: MTP inhibitor used to decrease VLDL</li><li>\u2022 MTP (microsomal triglyceride transfer protein) inhibitors, like lomitapide, are used to decrease very-low-density lipoprotein (VLDL) and LDL cholesterol levels by inhibiting the assembly and secretion of lipoproteins. Laropiprant is not an MTP inhibitor.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Laropiprant is used in combination with niacin to reduce niacin-induced flushing, improving the tolerability of niacin therapy, which is effective in managing dyslipidemia. It does not have hypolipidemic action on its own.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "434f5f07",
      "audio": ""
    },
    {
      "text": "Which of the following drug can reduce LDL cholesterol independent of its effect on LDL receptor density?",
      "options": [
        {
          "label": "A",
          "text": "Atorvastatin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Evolocumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Evinacumab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cholestyramine",
          "correct": false
        }
      ],
      "correct_answer": "C. Evinacumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Evinacumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option A: Atorvastatin</li><li>\u2022 Option A: Atorvastatin</li><li>\u2022 Atorvastatin is a statin that reduces LDL cholesterol levels primarily by inhibiting HMG-CoA reductase, which leads to an upregulation of LDL receptors on hepatocytes, increasing the clearance of LDL from the bloodstream. Its effect is dependent on LDL receptor density.</li><li>\u2022 Option B: Evolocumab</li><li>\u2022 Option B: Evolocumab</li><li>\u2022 Evolocumab is a PCSK9 inhibitor that lowers LDL cholesterol levels by increasing the number of LDL receptors available to clear LDL from the blood. It directly influences LDL receptor density.</li><li>\u2022 Option D: Cholestyramine</li><li>\u2022 Option D: Cholestyramine</li><li>\u2022 Cholestyramine is a bile acid sequestrant that lowers LDL cholesterol by binding bile acids in the intestine, preventing their reabsorption. This leads to an increased conversion of cholesterol to bile acids in the liver, which indirectly increases LDL receptor expression to clear more LDL from the blood.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Evinacumab reduces LDL cholesterol levels independent of LDL receptor density by inhibiting ANGPTL3, making it effective in conditions where traditional LDL receptor-dependent therapies are less effective.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5808e415",
      "audio": ""
    },
    {
      "text": "An experimental drug is found to preferentially dilate small autoregulatory coronary arterioles without affecting large conducting vessels. It is likely to:",
      "options": [
        {
          "label": "A",
          "text": "Evoke coronary steal phenomenon",
          "correct": true
        },
        {
          "label": "B",
          "text": "Mitigate classical angina but not variant angina",
          "correct": false
        },
        {
          "label": "C",
          "text": "Produce tachycardia as an adverse effect",
          "correct": false
        },
        {
          "label": "D",
          "text": "Useful in CHF",
          "correct": false
        }
      ],
      "correct_answer": "A. Evoke coronary steal phenomenon",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Evoke coronary steal phenomenon</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of Other Options:</li><li>\u2022 Option B: Mitigate classical angina but not variant angina</li><li>\u2022 Option B: Mitigate classical angina but not variant angina</li><li>\u2022 While preferential dilation of small coronary arterioles can theoretically improve blood flow to areas of the heart with atherosclerotic narrowing, it may not be as effective in mitigating classical angina as it does not address the underlying problem of fixed coronary obstruction effectively. Rather it may increase the frequency of anginal attacks due to coronary steal phenomenon. Variant (Prinzmetal's) angina is caused by vasospasm of the coronary arteries, which involves both large and small vessels. Since the drug does not affect large conducting vessels, it would not be effective in relieving the vasospasm characteristic of variant angina.</li><li>\u2022 Option C: Produce tachycardia as an adverse effect</li><li>\u2022 Option C: Produce tachycardia as an adverse effect</li><li>\u2022 Drugs that cause significant vasodilation can lead to reflex tachycardia as the body attempts to maintain blood pressure. However, this specific drug targets only the small coronary arterioles, and without systemic vasodilation, it is less likely to produce reflex tachycardia.</li><li>\u2022 Option D: Useful in CHF</li><li>\u2022 Option D: Useful in CHF</li><li>\u2022 In chronic heart failure (CHF), improving myocardial perfusion can be beneficial. However, for a drug to be useful in CHF, it generally needs to have systemic effects that reduce cardiac workload and improve overall hemodynamics. Preferential dilation of small coronary arterioles may improve local myocardial blood flow but is unlikely to provide significant benefit in the management of CHF, where broader systemic effects are often required.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drugs that preferentially dilate small autoregulatory coronary arterioles without affecting large conducting vessels can evoke the coronary steal phenomenon, where blood flow is diverted from ischemic to non-ischemic myocardial regions, potentially worsening ischemia. This selective action does not adequately address the mechanisms of classical or variant angina, nor does it provide comprehensive benefits for chronic heart failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ae339747",
      "audio": ""
    }
  ]
}